FDA Approves Expanded Use for Trikafta in Cystic Fibrosis
Vanzacaftor/tezacaftor/deutivacaftor (Alyftek) also received approval for the treatment of cystic fibrosis in people 6 years and older who have at least 1 F508del mutation.
Vanzacaftor/tezacaftor/deutivacaftor (Alyftek) also received approval for the treatment of cystic fibrosis in people 6 years and older who have at least 1 F508del mutation.
Pharmacists identify appropriate patients for new oral and antibody drug conjugate treatments and provide counseling to help patients navigate the evolving treatment landscape.
While most advanced prostate cancer is incurable, treatments can slow or shrink the cancer, reduce symptoms and extend a person’s life.
Preterm birth is the biggest cause of infant mortality and morbidity in the UK.1 Evidence has shown that optimal cord management (OCM), defined here as…
Varicella-zoster vaccination could prevent fatal outcome among individuals with disseminated herpes zoster.
bioRxiv – the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution
Women and girls have experienced some of the most brutal consequences of Sudan’s conflict. Eatizaz Yousif explains the role of the IRC in delivering essential…
The ACP Advocate is a bi-weekly e-newsletter that provides ACP members with news about public policy issues affecting internal medicine.
Compounding pharmacies have a 60- to 90-day grace period to complete production as it continues to monitor supply and demand.
This could be attributed to improved diet and health awareness.
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…